Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 – Industry Analysis, Size, Shares, Growth, Trends And Forecast

ResearchMoz include new market research report” Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019: Industry Size, Shares, Growth, Trends And Forecast” to its huge collection of research reports.

Browse PDF – Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 – Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need

Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 – Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need”, which provides insights into three therapeutic indications in gastrointestinal disorders in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of gastrointestinal disorders, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.

Reasons to Buy
 
The report will enhance your decision-making capability by allowing you to:
 
  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

View Full Report – http://www.researchmoz.us/gastrointestinal-therapeutics-in-asia-pacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-high-regional-unmet-need-report.html

Table of Contents

3 Gastrointestinal Therapeutics in Asia-Pacific Market – Marketed Products (Global)
3.1 Irritable Bowel Syndrome
3.2 Ulcerative Colitis
3.3 Crohn’s Disease
3.4 Key Marketed Products
3.4.1 Amitiza
3.4.2 Humira
3.4.3 Remicade
3.4.4 Simponi
3.4.5 Cimzia
3.4.6 Tysabri
4 Gastrointestinal Therapeutics in Asia-Pacific Market – Pipeline Analysis
4.1 Irritable Bowel Syndrome
4.1.1 Overall Pipeline
4.1.2 Pipeline Analysis by Molecule Type
4.1.3 Pipeline Analysis by Mechanism of Action
4.2 Ulcerative Colitis Pipeline
4.2.1 Overall Pipeline
4.2.2 Pipeline Analysis by Molecule Type
4.2.3 Pipeline Analysis by Mechanism of Action
4.2.4 Crohn’s Disease Pipeline
4.2.5 Overall Pipeline
4.2.6 Pipeline Analysis by Molecule Type
4.2.7 Pipeline Analysis by Mechanism of Action
4.3 Promising Drug Candidates in the Pipeline
4.3.1 GSK-1605786
4.3.2 MLN0002
4.3.3 EMD-61753
5 Gastrointestinal Therapeutics in Asia-Pacific Market – Market Forecast to 2019
5.1 Asia-Pacific Markets
5.1.1 Treatment Usage Patterns
5.1.2 Annual Cost of Therapy
5.1.3 Market Size
5.2 Australia
5.2.1 Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 India
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 China
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers
5.6.1 Drivers
5.6.2 Barriers
6 Gastrointestinal Therapeutics in Asia-Pacific Market – Deals and Strategic Consolidations (Global)
6.1 Deals Analysis
6.2 Major Co-Development Deals
6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide
6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn’s Disease
6.3 Major Licensing Deals
6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program
6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin
6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx

View Full Report – http://www.researchmoz.us/gastrointestinal-therapeutics-in-asia-pacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-high-regional-unmet-need-report.html

About ResearchMoz 

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

Website@ http://www.researchmoz.us/

Email: sales@researchmoz.us

Browse Blog – http://latestmarketstudy.blogspot.com/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s